in , , , , ,

F.D.A. Panel Declines to Endorse Controversial Alzheimer’s Drug

The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.

What do you think?

0 points
Upvote Downvote

Our Food Staff’s 21 Favorite Thanksgiving Recipes

Mastercard Foundation Scholars Program at Sciences Po 2020-2021 | Fully-Funded